Convalescent plasma
Convalescent Plasma Therapy
| Classification |
|
|---|---|
| External resources |
|
Convalescent plasma therapy is a form of passive immunity that involves the transfusion of plasma collected from individuals who have recovered from an infectious disease to patients currently battling the same disease. This therapy is based on the principle that the antibodies present in the convalescent plasma can help fight the infection in the recipient.
History[edit | edit source]
The use of convalescent plasma dates back to the early 20th century. It was first used during the Spanish flu pandemic of 1918-1919. Since then, it has been employed in various outbreaks, including Ebola virus disease, SARS, and MERS.
Mechanism of Action[edit | edit source]
Convalescent plasma contains antibodies that are specific to the pathogen causing the disease. When transfused into a patient, these antibodies can neutralize the virus or bacteria, thereby aiding the patient's immune system in clearing the infection. This form of therapy is particularly useful when no specific antiviral drugs or vaccines are available.
Applications[edit | edit source]
Convalescent plasma therapy has been used in the treatment of several infectious diseases, including:
Risks and Considerations[edit | edit source]
While convalescent plasma therapy can be beneficial, it is not without risks. Potential complications include:
- Allergic reactions
- Transfusion-related acute lung injury (TRALI)
- Transfusion-associated circulatory overload (TACO)
- Transmission of infectious agents
Regulatory Status[edit | edit source]
The use of convalescent plasma is subject to regulatory approval and guidelines, which vary by country. In the United States, the Food and Drug Administration (FDA) has provided emergency use authorization for convalescent plasma in certain situations.
Research and Efficacy[edit | edit source]
Ongoing research is evaluating the efficacy of convalescent plasma therapy in various infectious diseases. Clinical trials are essential to determine the optimal timing, dosage, and patient selection criteria for this treatment.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
